High levels of baseline ctDNA constitute a poor prognostic factor in progression-free survival in patients receiving neo-adjuvant chemo-immunotherapy: Results from NADIM clinical trial.

被引：0

作者：

Provencio, Mariano ^{[1
]}

Serna-Blasco, Roberto ^{[1
]}

Nadal, Ernest ^{[2
]}

Insa, Amelia ^{[3
]}

Rosario Garcia-Campelo, M. ^{[4
]}

Pereiro Corbacho, Diego ^{[5
]}

Domine, Manuel ^{[6
]}

Majem, Margarita ^{[7
]}

Rodriguez-Abreu, Delvys ^{[8
]}

Martinez-Marti, Alex ^{[9
]}

de Castro, Javier ^{[10
]}

Cobo, Manuel ^{[11
]}

Lopez-Vivanco, Guillermo ^{[12
]}

del Barco, Edel ^{[13
]}

Bernabe, Reyes ^{[14
]}

Vinolas, Nuria ^{[15
]}

Barneto, Isidoro ^{[16
]}

Viteri, Santiago ^{[17
]}

Pereira, Eva ^{[18
]}

Royuela, Ana ^{[1
]}

Casarrubios, Marta ^{[1
]}

Salas, Clara ^{[1
]}

Parra, Edwin R. ^{[19
]}

Wistuba, Ignacio ^{[19
]}

Calvo, Virginia ^{[1
]}

Laza-Briviesca, Raquel ^{[1
]}

Massuti, Bartomeu ^{[20
]}

Cruz-Vermudez, Alberto ^{[1
]}

Romero, Atocha ^{[1
]}

机构：

[1] Hosp Univ Puerta de Hierro Majadahonda, Madrid, Spain

[2] Inst Catala Oncol, Barcelona, Spain

[3] Hosp Clin Univ Valencia, Valencia, Spain

[4] Hosp Univ A Coruna, La Coruna, Spain

[5] Hosp Univ Vigo, Vigo, Pontevedra, Spain

[6] Hosp Univ Fdn JimenezDiaz, IIS FJD, Madrid, Spain

[7] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[8] Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain

[9] Hosp Univ Vall dHebron, Barcelona, Spain

[10] Hosp Univ La Paz, Madrid, Spain

[11] Hosp Univ Reg Malaga, Malaga, Spain

[12] Hosp Univ Cruces, Bilbao, Spain

[13] Hosp Univ Salamanca, Salamanca, Spain

[14] Hosp Univ Virgen del Rocio, Seville, Spain

[15] Hosp Clin Barcelona, Barcelona, Spain

[16] Hosp Univ Reina Sofia, Cordoba, Spain

[17] Hosp Univ Dexeus Quiron, Inst Oncol Dr Rosell, Barcelona, Spain

[18] Fdn GECP, Barcelona, Spain

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[20] Hosp Gen Univ Alicante, Alicante, Spain

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

560

引用

页数：2

共 8 条

[1] TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial
Cruz-Bermudez, A.
Casarrubios, M.
Briviesca, R. Laza
Nadal, E.
Insa, A.
Mosquera, J.
Huidobro, G.
Domine Gomez, M.
Massuti, B.
Majem Tarruella, M.
Rodriguez-Abreu, D.
Martinez-Marti, A.
De Castro Campeno, J.
Cobo Dols, M.
Lopez Vivanco, G.
Del Barco, E.
Bernabe Caro, R.
Vinolas, N.
Barneto, I.
Viteri, S.
Jove, M.
Romero, A.
Franco, F.
Provencio, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S543 - S543
[2] Predictive molecular parameters of pneumonitis development in stage IIIa NSCLC patients treated with neo-adjuvant chemo-immunotherapy from NADIM clinical trial
Sierra-Rodero, B.
Garitaonaindia, Y.
Martinez-Cutillas, M.
Nadal, E.
Insa, A.
Garcia Campelo, M. R.
Casal Rubio, J.
Domine Gomez, M.
Majem Tarruella, M.
Rodriguez Abreu, D.
Martinez-Marti, A.
De Castro Carpeno, J.
del Barco, E.
Vinolas, N.
Barneto Aranda, I. C.
Massuti Sureda, B.
Casarrubios, M.
Laza-Briviesca, R.
Cruz-Bermudez, A.
Provencio, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S740 - S740
[3] Molecular remission is an independent predictor of progression-free survival in patients with Waldenstrom macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study
Varettoni, Marzia
Zibellini, Silvia
Merli, Michele
Drandi, Daniela
Jimenez, Cristina
Furlan, Daniela
Ferretti, Virginia Valeria
Fabbri, Nicole
Dogliotti, Irene
Varraso, Chiara
Ferrante, Martina
Cappello, Emilia
Peri, Veronica
Cavalloni, Chiara
Borriero, Michela
Facchetti, Giulia Vittoria
Ferrero, Simone
Arcaini, Luca
Garcia-Sanz, Ramon
HEMATOLOGICAL ONCOLOGY, 2023, 41 (03) : 574 - 577
[4] Peripheral blood T-cell receptor immune repertoire characterization of resectable stage IIIA non-small cell lung cancer patients receiving neo-adjuvant chemo-immunotherapy treatment from NADIM study.
Cruz Bermudez, Alberto
Casarrubios, Marta
Laza Briviesca, Raquel
Sierra-Rodero, Belen
Barquin, Miguel
Romero, Atocha
Franco, Fernando
Calvo, Virginia
Nadal, Ernest
Insa, Amelia
Garcia-Campelo, Rosario
Casal, Joaquin
Domine, Manuel
Massuti, Bartomeu
Majem, Margarita
Rodriguez-Abreu, Delvys
Martinez-Marti, Alex
De Castro, Javier
Provencio-Pulla, Mariano
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Genetic polymorphisms to predict progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone therapy: Results from the NCI 9012 trial.
Albany, Costantine
Daignault-Newton, Stephanie
Skaar, Todd C.
Ipe, Joseph
Siddiqui, Javed
Twardowski, Przemyslaw
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[6] Obinutuzumab as Consolidation After Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance From Bone Marrow and Peripheral Blood Resulting in Improved Progression-Free Survival: Results of UK NCRI Phase II/III GALACTIC Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 16 - 17
[7] Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood resulting in improved Progression-free survival: Results of UK NCRI Phase II/III GALACTIC trial
Munir, Talha
Howard, Dena
Hockaday, Anna
Oughton, Jamie
Emmerson, Jake
Phillips, David
Neilson, Jeff
Pemberton, Nicholas
Paneesha, Shankara
Kennedy, Ben
Rawstron, Andrew
Hillmen, Peter
LEUKEMIA & LYMPHOMA, 2020, 61 : 209 - 210
[8] Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO)
Lebellec, L.
Bertucci, F.
Tresch-Bruneel, E.
Bompas, E.
Toiron, Y.
Camoin, L.
Mir, O.
Laurence, V.
Clisant, S.
Decoupigny, E.
Blay, J-Y.
Goncalves, A.
Penel, N.
ANNALS OF ONCOLOGY, 2016, 27

← 1 →